Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study

Trial Profile

Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 13 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top